aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.08−0.91 (-18.24%)
Close on Nov 18, 2026Market cap $400.20MP/E –Yield –
aTYR PHARMA operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
aTYR PHARMA's operating cash flow for the twelve months ending Jun 30, 2026 was -$54.54M. For fiscal 2025 it was -$61.99M. The highest annual figure on record is -$15.30M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$61.99M | – |
| FY2024 | Dec 31, 2024 | -$69.12M | – |
| FY2023 | Dec 31, 2023 | -$33.22M | – |
| FY2022 | Dec 31, 2022 | -$41.89M | – |
| FY2021 | Dec 31, 2021 | -$33.08M | – |
| FY2020 | Dec 31, 2020 | -$15.30M | – |
| FY2019 | Dec 31, 2019 | -$20.01M | – |
| FY2018 | Dec 31, 2018 | -$31.06M | – |
| FY2017 | Dec 31, 2017 | -$42.36M | – |
| FY2016 | Dec 31, 2016 | -$52.86M | – |
| FY2015 | Dec 31, 2015 | -$36.80M | – |
| FY2014 | Dec 31, 2014 | -$22.82M | – |
| FY2013 | Dec 31, 2013 | -$17.31M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.52M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.89M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.16M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$590.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.12M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.83M | -383.1% |
| Q4 FY2020 | Dec 31, 2020 | -$5.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.40M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.82M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.46M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.31M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.89M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.70M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.69M | – |
See a number that looks wrong?